Chimerix Inc
Chimerix, Inc., a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases in the United States. Its product pipeline comprising dordaviprone (ONC201), which is in phase 3 clinical-stage development for H3 K27M-mutant diffuse glioma, as well as in phase 2 Investigator Initiated Clinical Trials for multiple oncology studies; and ONC206, a sec… Read more
Market Cap & Net Worth: Chimerix Inc (CMRX)
Chimerix Inc (NASDAQ:CMRX) has a market capitalization of $801.08 Million ($801.08 Million) as of March 19, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #8831 globally and #4364 in its home market, demonstrating a 0.12% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Chimerix Inc's stock price $8.54 by its total outstanding shares 93803800 (93.80 Million).
Chimerix Inc Market Cap History: 2015 to 2025
Chimerix Inc's market capitalization history from 2015 to 2025. Data shows change from $839.54 Million to $801.08 Million (-13.87% CAGR).
Index Memberships
Chimerix Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.20 Trillion | 0.03% | #245 of 976 |
|
NASDAQ Composite
IXIC
|
$32.97 Trillion | 0.00% | #941 of 3165 |
Weight: Chimerix Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Chimerix Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Chimerix Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1539.80x
Chimerix Inc's market cap is 1539.80 times its annual revenue
1740.90x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $839.54 Million | $10.76 Million | -$117.37 Million | 78.01x | N/A |
| 2016 | $431.50 Million | $5.70 Million | -$76.39 Million | 75.67x | N/A |
| 2017 | $434.31 Million | $4.49 Million | -$70.98 Million | 96.64x | N/A |
| 2018 | $241.08 Million | $7.22 Million | -$69.47 Million | 33.41x | N/A |
| 2019 | $190.42 Million | $12.52 Million | -$173.65 Million | 15.21x | N/A |
| 2020 | $453.07 Million | $5.37 Million | -$42.13 Million | 84.34x | N/A |
| 2021 | $603.16 Million | $1.98 Million | -$255.79 Million | 304.78x | N/A |
| 2022 | $174.48 Million | $33.82 Million | $172.17 Million | 5.16x | 1.01x |
| 2023 | $90.29 Million | $324.00K | -$82.09 Million | 278.66x | N/A |
| 2024 | $326.44 Million | $212.00K | -$88.39 Million | 1539.80x | N/A |
Competitor Companies of CMRX by Market Capitalization
Companies near Chimerix Inc in the global market cap rankings as of March 19, 2026.
Key companies related to Chimerix Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #165 globally with a market cap of $114.33 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #285 globally with a market cap of $73.32 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #340 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #497 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #165 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $114.33 Billion | $451.59 |
| #285 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $73.32 Billion | $744.12 |
| #340 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #497 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Chimerix Inc Historical Marketcap From 2015 to 2025
Between 2015 and today, Chimerix Inc's market cap moved from $839.54 Million to $ 801.08 Million, with a yearly change of -13.87%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $801.08 Million | +145.40% |
| 2024 | $326.44 Million | +261.56% |
| 2023 | $90.29 Million | -48.25% |
| 2022 | $174.48 Million | -71.07% |
| 2021 | $603.16 Million | +33.13% |
| 2020 | $453.07 Million | +137.93% |
| 2019 | $190.42 Million | -21.01% |
| 2018 | $241.08 Million | -44.49% |
| 2017 | $434.31 Million | +0.65% |
| 2016 | $431.50 Million | -48.60% |
| 2015 | $839.54 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 19th, 2026 the market cap of Chimerix Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $801.08 Million USD |
| MoneyControl | $801.08 Million USD |
| MarketWatch | $801.08 Million USD |
| marketcap.company | $801.08 Million USD |
| Reuters | $801.08 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.